NewAmsterdam Pharma Company N.V. Proceeds From Borrowings Classified As Financing Activities
NewAmsterdam Pharma Company N.V. (NAMS) reported Proceeds From Borrowings Classified As Financing Activities of EUR 11.32 million for the 12-month period ending 2020-12-31, per its 20-F/A filed 2024-10-28.
Financial Statements › Cash Flow › Financing Activities
ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities · last filed 2024-10-28
| Period end | Proceeds From Borrowings Classified As Financing Activities 12 month |
|---|---|
| 2020-12-31 | 11.32M EUR 20-F/A · filed 2024-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |